HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology

Nelson, Edward L.

doi:10.4155/cli.14.62

Cited by 12 publications

(9 citation statements)

References 385 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Regarding chondrosarcoma, the level of immunohistochemical expression of HER-2 was similar in all cases as we didn’t find membranous staining in any of the examined cases. Our findings were just identical to those reported by Nelson et al and Park et al, [ 17 ] [ 29 ] who couldn’t detect immunohistochemical staining of HER-2 in their chondrosarcoma cases. Therefore, it is unlikely that targeted therapy against HER-2 overexpression could be used effectively in the treatment of such miserable patients also experiencing well-known resistance to most chemotherapeutic regimens.…”

Section: Discussionsupporting

confidence: 92%

“…The HER-2 expression has been recognised in some tumour types mainly breast, gastric, oesophageal, pancreatic, and many others. Even though there are agreement about antibodies and tyrosine kinase inhibitors targeting HER-2 in the breast, gastric and oesophagal adenocarcinomas, still there are other evident prospects in other tumour types [ 17 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

HER-2 Immunohistochemical Expression in Bone Sarcomas: A New Hope for Osteosarcoma Patients

Khalifa¹,

Fathy²

2018

Open Access Maced J Med Sci

View full text Add to dashboard Cite

BACKGROUND:Osteosarcoma and chondrosarcoma, remain the most common primary bone tumours. Questions have been raised about the prognostic influence of HER-2 in bone sarcomas, but so far the results have been debatable. The her-2 expression is possibly a predictor of chemotherapy response.AIM:In this study, we investigated the extent of HER-2 expression in bone sarcomas, and attempted to correlate it with pertinent variables that will help to provide better treatment options, especially for metastatic ones.MATERIAL AND METHODS:Fifty-two cases of bone sarcomas (32 osteosarcoma cases and 20 chondrosarcoma ones) were studied for HER-2 immunohistochemical expression then correlation with all available clinicopathologic features was done.RESULTS:Most of the osteosarcoma cases exhibited membranous staining (78.1%). Strong staining was observed (score 3+) in 34.4%; while 21.9% showed moderate staining (score 2+); and 21.9% displayed weak staining (score 1+), on the other hand, no staining was detected in 7 out of 32 cases (21.9%) (score 0). As regards chondrosarcoma, the absence of staining in all examined cases was noted. Immunohistochemical HER-2 overexpression correlated significantly with osteosarcoma site with P value = 0.004, with variation relating HER-2 intensity score to the site of osteosarcoma (P = 0.051). A statistically significant negative correlation was detected between HER-2 expression and the presence of metastasis at time of diagnosis (P = 0.006), A significant correlation was also found regarding HER-2 score and presence of metastasis with P value = 0.046 as more than half of cases with no metastasis at diagnosis (17/28 cases, 60.7%) showed positive intensity score. A statistically significant correlation was detected between HER-2 expression and patients’ age (P = 0.044). Also, HER-2 expression significantly correlated to histopathological detection of fibrous tissue, with P value = 0.033. Higher scores of HER-2 expression were associated with a significantly better differentiation (P = 0.038) since detection of wide areas of osteoid were associated with higher HER-2 scores.CONCLUSION:Further research would still be needed to delineate HER-2 role being a new hope for therapeutic targeting in bone sarcoma patients, mainly osteosarcoma in contrast to chondrosarcoma that didn’t express HER-2 at all.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

HER-2 Immunohistochemical Expression in Bone Sarcomas: A New Hope for Osteosarcoma Patients

Khalifa¹,

Fathy²

2018

Open Access Maced J Med Sci

View full text Add to dashboard Cite

show abstract

“…HER2 is found to be over expressed in several breast cancers and correlates with tumor size and estrogen expression. Additionally, HER2 expression was reported to be amplified in 20–25% of breast cancers and acted as an indicator of poor prognosis [ 37 ]. On the other hand, mutations, aberrant or deregulated expression of TP53 , MDM2 and RB genes have also been implicated to play a key role in therapeutic responses to breast cancer [ 38 ].…”

Section: Breast Cancermentioning

confidence: 99%

Potential Diagnostic and Therapeutic Applications of Oligonucleotide Aptamers in Breast Cancer

Shaikh

et al. 2017

IJMS

View full text Add to dashboard Cite

Breast cancer is one of the most common causes of cancer related deaths in women. Currently, with the development of early detection, increased social awareness and kinds of treatment options, survival rate has improved in nearly every type of breast cancer patients. However, about one third patients still have increased chances of recurrence within five years and the five-year relative survival rate in patients with metastasis is less than 30%. Breast cancer contains multiple subtypes. Each subtype could cause distinct clinical outcomes and systemic interventions. Thereby, new targeted therapies are of particular importance to solve this major clinical problem. Aptamers, often termed “chemical antibodies”, are functionally similar to antibodies and have demonstrated their superiority of recognizing target with high selectivity, affinity and stability. With these intrinsic properties, aptamers have been widely studied in cancer biology and some are in clinical trials. In this review, we will firstly discuss about the global impacts and mechanisms of breast cancer, then briefly highlight applications of aptamers that have been developed for breast cancer and finally summarize various challenges in clinical translation of aptamers.

show abstract

“…Overactivity and overexpression of these proteins have also been implicated in the formation of malignancies of the Skin, Genitourinary tract, gastrointestinal tract, Head and Neck and Prostate. Our grasp of their complex function and molecular regulatory networks has fuelled the development of revolutionary therapeutic options in the management of cancers over the last decade [4].…”

Section: Introductionmentioning

confidence: 99%

“…The HER2/neu protein has been demonstrated to be an effective target in molecular therapy of metastatic cancers of the breast and stomach, via the use of monoclonal antibodies [e.g. Transtuzumab] specific for the Her-2/neu protein [4] [5]. Similarly, the use of monoclonal antibodies such as Cetuximab and the tyrosine kinase inhibitors, Gefitinib and Erlotinib, targeting EGFR has been rewarding in the treatment of non-small cell lung cancer, as well as cancers of the colon, pancreas and the prostate [6].…”

Section: Introductionmentioning

confidence: 99%

Expression of HER Receptor Proteins in Prostate Adenocarcinoma: A Perspective from North Central Nigeria

Ajetunmobi¹,

Drebber²,

Buettner³

et al. 2019

OJPathology

View full text Add to dashboard Cite

Introduction: Members of the Human Epidermal Receptor [HER] family of receptor tyrosine kinases, such as HER2 and EGFR proteins are overexpressed in several epithelial malignancies and serve as effective therapeutic targets in cancer management. However, their role in prostate cancer development has been sparingly explored and with contrasting findings. Notably their relationship with prostate cancers cases seen in Sub-Saharan Africa is yet to be explored. Design: A retrospective study involving histologically diagnosed cases of adenocarcinomas of the prostate. Cases were classed according to the WHO/ISUP Gleason Prognostic groups [G1-G5]. Immunohistochemical analysis was performed using monoclonal antibodies for HER2 and EGFR, while in situ hybridization employed DNA probes for the corresponding genes. Scores of +2 and +3 were regarded as positive for both antibodies, while a target gene: centromere ratio of >2 was set as the threshold for amplification. Results: A total of 44 cases were included in the study. The acinar type was the commonest morphologically, with Gleason group 5 [Gleason scores 8-10] accounting for close to half of the cases [47.7%]. The HER2 antibody stained negatively in the majority of cases [93.2%], being positive in only 3 [6.8%] of cases seen. High level expression of EGFR [+2/+3] was observed in 25% of cases, low level expression was identified in 6 [13.6%] cases. All HER2 positive malignancies displayed overexpression of EGFR. In situ-hybridization revealed the absence of high level amplification for both HER2 and EGFR, while polysomy was not detected in any of the cases.

show abstract

HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology

Cited by 12 publications

References 385 publications

HER-2 Immunohistochemical Expression in Bone Sarcomas: A New Hope for Osteosarcoma Patients

HER-2 Immunohistochemical Expression in Bone Sarcomas: A New Hope for Osteosarcoma Patients

Potential Diagnostic and Therapeutic Applications of Oligonucleotide Aptamers in Breast Cancer

Expression of HER Receptor Proteins in Prostate Adenocarcinoma: A Perspective from North Central Nigeria

Contact Info

Product

Resources

About